Aerska
PrivateLast Round
Series A
May 20, 2026
Total Funding Raised
$70M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Aerska operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was a Series A round in May 2026.
Aerska is a biotechnology company developing RNA interference (RNAi) medicines designed to treat, delay, and prevent diseases of the brain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aerska Comparables
Compare Aerska with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cenos Therapeutics | 90% | |
| Gate2Brain | 84% | |
| Biorchestra Co., Ltd. | 83% |
For institutional investors. Book with your work email.
Aerska Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 20, 2026 | ||||
| Series A | Feb 9, 2026 | ||||
| Seed | Oct 1, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aerska Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Iaso Ventures | Series A |
| Backed VC | Seed |
| Saras Capital | Seed |
| Lingotto | Seed |
| BlueYard Capital | Seed |
| Ada Ventures | Seed |
| age1 | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 26, 2026
Grew 30% QoQ, from 27 to 35 employees.
- Jul 18, 2026
Grew 27% QoQ, from 22 to 28 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 17, 2026
Aerska, Inc. appoints Laura Sepp-Lorenzino to its Scientific Advisory Board on Sep 17th '26 in Ireland and the United Kingdom, supporting the progression of its antibody-oligo conjugate platform and RNA therapeutics pipeline for neurological disease.
For institutional investors. Book with your work email.
Aerska Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aerska's valuation, stock price, and market status.
Is Aerska a public or private company?
Aerska is a private company.
What is the current stock price of Aerska?
Aerska is a private company, so its shares have no public market price. Caplight tracks Aerska's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aerska worth (valuation)?
Valuation information for Aerska is not publicly available.
Can I buy Aerska stock?
Aerska shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aerska's last funding round?
Aerska's most recent funding round was Series A on May 20, 2026.
Who are the main investors in Aerska?
Key investors in Aerska include Backed VC, age1, Speedinvest, LSP Dementia Fund.
Will Aerska IPO soon?
No public IPO plans have been announced for Aerska.
How can I track Aerska secondary market activity?
Caplight tracks bids, offers, and trades in Aerska's shares on secondary markets.